Rilonacept

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Rilonacept
Clinical data
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • none
UNII
ChEMBL
 ☒N☑Y (what is this?)  (verify)

Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.[1]

Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.[2]

Rilonacept was given an "orphan drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome and neonatal onset multisystem inflammatory disease (It is not approved in the U.S. on this indication).[3]

On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[4]

References[edit]

  1. ^ Terkeltaub, R; Sundy, J S; Schumacher, H R; Murphy, F; Bookbinder, S; Biedermann, S; Wu, R; Mellis, S; Radin, A (2009). "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study". Annals of the Rheumatic Diseases. 68 (10): 1613–1617. doi:10.1136/ard.2009.108936. PMC 2732898. PMID 19635719.
  2. ^ "Molecule of the month. Rilonacept". Drug News & Perspectives. 21 (4): 232. 2008. PMID 18560622.
  3. ^ "Arcalyst FDA Approval History - Drugs.com". Archived from the original on 2012-05-16. Retrieved 2012-05-08.
  4. ^ "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". Archived from the original on 2012-05-21. Retrieved 2012-05-08.

External links[edit]